Optimised electroporation mediated DNA vaccination for treatment of prostate cancer

Genetic Vaccines and Therapy

Volumn 8, Issue , 2010, Pages

  Ahmad, Sarfraz ^a,b,c   Casey, Garrett ^a,b   Sweeney, Paul ^a,b,c   Tangney, Mark ^a,b   O'Sullivan, Gerald C ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; OLIGODEOXYNUCLEOTIDE; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA IMMUNIZATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; HISTOPATHOLOGY; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; QUADRICEPS FEMORIS MUSCLE; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALIA; MUS; PROKARYOTA;

EID: 77649223949     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-8-1     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009, 8:51-66. 10.1586/14760584.8.1.51, 19093773.
3. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995, 46:681-686. 10.1016/S0090-4295(99)80301-X, 7495121.
4. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995, 7:175-184. 10.1097/00001622-199503000-00014, 7756383.
5. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 1996, 17:39-45. 10.1016/0167-5699(96)80567-6, 8652051.
6. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366. 10.1126/science.274.5291.1363, 8910274.
7. Schellhammer PF, Bracken RB, Bean MA, Pinsky CM, Whitmore WF. Immune evaluation with skin testing. A study of testicular, prostatic, and bladder neoplasms. Cancer 1976, 38:149-156. 10.1002/1097-0142(197607)38:1<149::AID-CNCR2820380124>3.0.CO;2-Q, 947511.
8. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998, 82:568-573.
9. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997, 30:73-78. 10.1002/(SICI)1097-0045(19970201)30:2<73::AID-PROS1>3.0.CO;2-L, 9051144.
10. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997, 89:293-300. 10.1093/jnci/89.4.293, 9048833.
11. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993, 90:11478-11482. 10.1073/pnas.90.24.11478, 48007, 8265577.
12. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998, 46:82-87. 10.1007/s002620050465, 9558003.
13. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996, 6:11-24. 10.1097/00008390-199602000-00003, 8640065.
14. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993, 53:227-230.
15. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998, 95:1735-1740. 10.1073/pnas.95.4.1735, 19171, 9465086.
16. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 1999, 96:14523-14528. 10.1073/pnas.96.25.14523, 24469, 10588738.
17. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer Growth. Mol Ther 2009, 17(6):1101-8. 10.1038/mt.2009.66, 19337234.
18. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145:907-923.
19. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001, 38:633-651. 10.1258/0004563011901055, 11732646.
20. Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 2001, 20:4497-4506. 10.1038/sj.onc.1204542, 11494145.
21. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005, 62:217-223. 10.1002/pros.20135, 15389792.
22. Drabick JJ, Glasspool-Malone J, King A, Malone RW. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 2001, 3:249-255. 10.1006/mthe.2000.0257, 11237682.
23. Lee DJ, Corr M, Carson DA. Control of immune responses by gene immunization. Ann Med 1998, 30:460-468. 10.3109/07853899809002487, 9814832.
24. Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabongkot J, Torii M, Tsuboi T, Kumar N. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 2004, 22:3205-3213. 10.1016/j.vaccine.2003.11.060, 15297075.
25. Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther 2005, 12:540-551. 10.1038/sj.cgt.7700810, 15678150.
26. Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL, Schellhammer PF, Qian J, Ciavarra RP. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer 2003, 107:773-780. 10.1002/ijc.11464, 14566827.
27. Collins CG, Tangney M, Larkin JO, Casey G, Whelan MC, Cashman J, Murphy J, Soden D, Vejda S, McKenna S, et al. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors. Cancer Gene Ther 2006, 13:1061-1071. 10.1038/sj.cgt.7700976, 16874363.
28. Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 1961, 86:228-239.
29. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003, 63:3281-3288.
30. Grossmann ME, Davila E, Celis E. Avoiding Tolerance Against Prostatic Antigens With Subdominant Peptide Epitopes. J Immunother (1991) 2001, 24:237-241. 10.1097/00002371-200105000-00007, 11395639.
31. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549. 10.1038/374546a0, 7700380.
32. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188:2335-2342. 10.1084/jem.188.12.2335, 2212431, 9858519.
33. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol 1996, 167:72-78. 10.1006/cimm.1996.0009, 8548847.
34. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998, 160:870-876.
35. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000, 164:1617-1624.
36. Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe?. Cancer Res 2000, 60:2571-2575.
37. Motta S, Castiglione F, Lollini P, Pappalardo F. Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res 2005, 1:5. 10.1186/1745-7580-1-5, 1287065, 16305756.
38. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760. 10.1146/annurev.immunol.20.100301.064842, 11861616.
39. Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, Busch DH, Wagner H. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol 2003, 170:2802-2805.
40. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998, 188:1075-1082. 10.1084/jem.188.6.1075, 2212529, 9743526.
41. Roos AK, King A, Pisa P. DNA vaccination for prostate cancer. Methods Mol Biol 2008, 423:463-472. full_text, 18370222.
42. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997, 3:362-371. 2230213, 9234241.
43. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D, Desjardins M. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 425:402-406. 10.1038/nature01912, 14508490.
44. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003, 425:397-402. 10.1038/nature01911, 14508489.
45. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974. 10.1146/annurev.immunol.18.1.927, 10837079.
46. Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E, Pisa P. Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother 2004, 53:1085-1092. 10.1007/s00262-004-0559-z, 15696608.
47. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96:4262-4267. 10.1073/pnas.96.8.4262, 16320, 10200250.
48. Satkauskas S, Bureau MF, Puc M, Mahfoudi A, Scherman D, Miklavcic D, Mir LM. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol Ther 2002, 5:133-140. 10.1006/mthe.2002.0526, 11829520.
49. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003, 177:437-447. 10.1046/j.1365-201X.2003.01093.x, 12648161.
50. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296. 10.1146/annurev.immunol.25.022106.141609, 17134371.
51. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006, 90:51-81. full_text, 16730261.
52. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007, 12:4957-4971. 10.2741/2441, 17569623.
53. Li CY, Huang Q, Kung HF. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol 2005, 2:81-91.
54. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20:1269-1278. 10.1089/hum.2009.067, 19619001.